192 related articles for article (PubMed ID: 29679773)
1. Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.
Scordo M; Morjaria SM; Littmann ER; Bhatia A; Chung HH; Maloy M; DeAngelis LM; Giralt SA; Taur Y; Sauter CS
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1914-1919. PubMed ID: 29679773
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
[TBL] [Abstract][Full Text] [Related]
6. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Schenone L; Houillier C; Tanguy ML; Choquet S; Agbetiafa K; Ghesquières H; Damaj G; Schmitt A; Bouabdallah K; Ahle G; Gressin R; Cornillon J; Houot R; Marolleau JP; Fornecker LM; Chinot O; Peyrade F; Bouabdallah R; Moluçon-Chabrot C; Gyan E; Chauchet A; Casasnovas O; Oberic L; Delwail V; Abraham J; Roland V; Waultier-Rascalou A; Willems L; Morschhauser F; Fabbro M; Ursu R; Thieblemont C; Jardin F; Tempescul A; Malaise D; Touitou V; Nichelli L; Le Garff-Tavernier M; Plessier A; Bourget P; Bonmati C; Wantz-Mézières S; Giordan Q; Dorvaux V; Charron C; Jabeur W; Hoang-Xuan K; Taillandier L; Soussain C;
Bone Marrow Transplant; 2022 Jun; 57(6):966-974. PubMed ID: 35422077
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
10. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
12. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
13. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
16. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
[TBL] [Abstract][Full Text] [Related]
17. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
Wada F; Nishikori M; Hishizawa M; Watanabe M; Aiba A; Kitano T; Shimazu Y; Shindo T; Kondo T; Takaori-Kondo A
Int J Hematol; 2020 Nov; 112(5):609-613. PubMed ID: 32980953
[TBL] [Abstract][Full Text] [Related]
18. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.
Tanaka Y; Sakai T; Tsunemine H; Ito T; Arima N
J Clin Exp Hematop; 2024 Mar; 64(1):32-36. PubMed ID: 38417873
[TBL] [Abstract][Full Text] [Related]
20. Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma.
Delphine L; Pierre-Edouard D; Bruno R; Bérengère G; Magalie J; Patrick V; Jean-Pierre M; Pierre M
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36810481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
